Hexagon Bio raises $62M to advance a novel ADC payload

What happened

Hexagon Bio closed a $62 million Series C led by The Column Group. The company plans to use the proceeds for a first-in-human study of HEX-360, expected in the first half of 2027, and to expand its antibody-drug conjugate platform.

Why it matters

HEX-360 uses a translation-inhibitor payload intended to work differently from commonly used ADC payloads. The approach is designed to address resistance and tolerability limitations in existing treatments.

The bigger picture

The programme remains preclinical. Animal and laboratory results can justify further development, but they do not establish safety or efficacy in patients.